Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab versus Rebif in relapsing-remitting multiple sclerosis (Study One)
ISRCTN21534255Phase 3Completed
- Sponsor
- Sanofi
- Start
- Sep 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised trial of alemtuzumab in multiple sclerosis (MS) (2 arms), sponsored by Sanofi. Primary endpoints: Time to sustained accumulation of disability and Relapse rate. Started Sep 2007; status: completed.
02
Drugs
alemtuzumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on ISRCTN21534255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN21534255.